The US FDA and the European Medicines Agency (EMA) will launch a three-year pilot program on 1 April to evaluate relevant quality data for new medicines. The Quality by Design (QbD) of pharmaceuticals involves an enhanced systematic and science-based approach to development and manufacturing, to better ensure product quality.
Pharma Times
Monday 21 March 2011
FDA and EMA start QbD pilot
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment